IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
IGC Pharma, Inc. (IGC)
NASDAQ:AMEX Investor Relations:
igcinc.us/investor-center/overview
Company Research
Source: Business Wire
-- Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's -- POTOMAC, Md.--(BUSINESS WIRE)--IGC Pharma, Inc (NYSE American: IGC) ("IGC" or the "Company"), today announced patient enrollment at Neurostudies, Inc. in Port Charlotte, Florida, for its Phase 2 clinical trial investigating IGC-AD1 as a potential treatment for Agitation in Alzheimer's disease.IGC Pharma is currently conducting a Phase 2 trial with IGC-AD1, a partial CB1r agonist with anti-neuroinflammatory properties and an inflammasome inhibitor, to treat Agitation in dementia due to Alzheimer's disease. Neuroinflammation, neurotransmitter imbalance, loss of CB1r, and inflammasome-3 have been implicated in Agitation and aggression in patients who have dementia due to Alzheimer's. IGC-AD1 contains low doses of Tetrahydrocannabinol ("THC") as one of its two active pharmaceutical agents. THC is the principal psychoactive cannabinoid found in Cannabis. IGC-AD1 is a first-of-its-kind THC-based
Show less
Read more
Impact Snapshot
Event Time:
IGC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IGC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IGC alerts
High impacting IGC Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
IGC
News
- IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's TreatmentBusiness Wire
- IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's DiseaseBusiness Wire
- IGC Announces Results of its 2024 Annual Stockholders MeetingBusiness Wire
- IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's DiseaseBusiness Wire
- IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 AgonistBusiness Wire
IGC
Sec Filings
- 9/27/24 - Form 8-K
- 9/27/24 - Form 4
- 8/27/24 - Form 8-K
- IGC's page on the SEC website